M. Margaret Prechel
  • Assistant Professor
  • Pathology
  • Thoracic and Cardiovascular Surgery
Research Keywords
  • Inflammation
  • Autoimmune
  • Autoimmunity
  • Blood Diseases
  • Pineal Gland
  • Thrombosis
  • Vascular Biology
  • Blood/Blood Products/Transfusions
  • Cardiovascular System
  • Cerebrovascular Disorders
  • Cytokines
  • Diabetes
  • Extracellular Matrix

Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopeniaWalenga,J. M.; Prechel,M.; Hoppensteadt,D.; Escalante,V.; Chaudhry,T.; Jeske,W. P.; Bakhos,M.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013 ;19(5):482-487

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced ThrombocytopeniaPrechel,M. M.; Walenga,J. M.Thrombosis journal 2013 ;11(1):7-9560-11-7

A colorimetric, metabolic dye reduction assay detects highly activated platelets: application in the diagnosis of heparin-induced thrombocytopenia.Prechel,M. M.; Escalante,V.; Drenth,A. F.; Walenga,J. M.Platelets 2012 ;23(1):69-80

Simple scoring system for early management of heparin-induced thrombocytopenia.Messmore,H. L.; Fabbrini,N.; Bird,M. L.; Choudhury,A. M.; Cerejo,M.; Prechel,M.; Jeske,W. P.; Siddiqui,A.; Thethi,I.; Wehrmacher,W. H.; Walenga,J. M.Clinical & Applied Thrombosis/Hemostasis 2011 ;17(2):197-201

Laboratory methods and management of patients with heparin-induced thrombocytopenia.Prechel,M.; Jeske,W. P.; Walenga,J. M.Methods in Molecular Biology 2010 ;663( ):133-156

Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.Prechel,M. M.; Jeske,W. P.; Walenga,J. M.Thrombosis research 2010 ;125(4):e143-8

Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes.Diaz,J.; Prechel,M.; Emanuele,M.; Emanuele,N.; Walenga,J. M.Clinical & Applied Thrombosis/Hemostasis 2010 ;16(2):121-125

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.Rao,N. V.; Argyle,B.; Xu,X.; Reynolds,P. R.; Walenga,J. M.; Prechel,M.; Prestwich,G. D.; MacArthur,R. B.; Walters,B. B.; Hoidal,J. R.; Kennedy,T. P.American Journal of Physiology - Cell Physiology 2010 ;299(1):97-110

Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery.Gluckman,T. J.; Segal,J. B.; Schulman,S. P.; Shapiro,E. P.; Kickler,T. S.; Prechel,M. M.; Conte,J. V.; Walenga,J. M.; Shafique,I.; Rade,J. J.Journal of Thrombosis & Haemostasis 2009 ;7(9):1457-1464

The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an updatePrechel,M.; Walenga,J. M.Seminars in Thrombosis & Hemostasis 2008 ;34(1):86-96

Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled HeparinFareed,J.; Walenga,J. M.; Jeske,W. P.; Hoppensteadt,D.; Prechel,M.; Iqbal,O.; Adiguzel,C.; Clark,M.; Litinas,E.; cunanan,J.; Linhardt,R.; Harenberg,J.Seminars in thrombosis and hemostatis 2008 ;34(supplement 1):119-127

Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting.Untch,B. R.; Jeske,W. P.; Schwartz,J.; Botkin,S.; Prechel,M.; Walenga,J. M.; Bakhos,M.Clinical & Applied Thrombosis/Hemostasis 2008 ;14(2):141-148

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing.Walenga,J. M.; Drenth,A. F.; Mayuga,M.; Hoppensteadt,D. A.; Prechel,M.; Harder,S.; Watanabe,H.; Osakabe,M.; Breddin,H. K.Clinical & Applied Thrombosis/Hemostasis 2008 ;14(3):325-331

Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.Walenga,J. M.; Prechel,M.; Jeske,W. P.; Hoppensteadt,D.; Maddineni,J.; Iqbal,O.; Messmore,H. L.; Bakhos,M.British journal of haematology 2008 ;143(1):92-99

Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopeniaWalenga,J. M.; Prechel,M.; Jeske,W. P.; Bakhos,M.Current opinion in pulmonary medicine 2005 ;11(5):385-391

Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin.Prechel,M. M.; McDonald,M. K.; Jeske,W. P.; Messmore,H. L.; Walenga,J. M.Journal of Thrombosis & Haemostasis 2005 ;3(10):2168-2175

Laboratory methods for heparin-induced thrombocytopenia.Prechel,M.; Jeske,W. P.; Walenga,J. M.Methods in Molecular Medicine 2004 ;93( ):83-93

Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugsWalenga,J. M.; Jeske,W. P.; Prechel,M. M.; Bacher,P.; Bakhos,M.Seminars in Thrombosis & Hemostasis 2004 ;30(Suppl 1):69-80

Newer insights on the mechanism of heparin-induced thrombocytopenia.Walenga,J. M.; Jeske,W. P.; Prechel,M. M.; Bakhos,M.Seminars in Thrombosis & Hemostasis 2004 ;30(Suppl 1):57-67

Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases.Porcelli,R.; Moskowitz,B. C.; Cetta,F.; Graham,L. C.; Godwin,J. E.; Eidem,B. W.; Prechel,M. M.; Walenga,J. M.Texas Heart Institute Journal 2003 ;30(1):58-61